Clincosm LogoSign in Get a demo

neuroblastoma recurrent

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)

Recruiting
  • Neuroblastoma Recurrent
  • Natural killer cell
  • +4 more
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Feb 22, 2023

Refractory Cancer, Refractory Tumor, Cancer Pediatric Trial in United States (9-ING-41, Irinotecan, Temozolomide)

Recruiting
  • Refractory Cancer
  • +10 more
  • Aurora, Colorado
  • +7 more
Dec 31, 2022

Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)

Terminated
  • Neuroblastoma Recurrent
  • Naxitamab and GM-CSF in combination with irinotecan and temozolomide
  • Hong Kong, Hong Kong
  • +2 more
Nov 8, 2022

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Neuroblastoma Recurrent, Neuroblastoma Trial in Worldwide (177Lu-DOTATATE)

Recruiting
  • Neuroblastoma Recurrent
  • Neuroblastoma
  • 177Lu-DOTATATE
  • Copenhagen, Denmark
  • +5 more
May 25, 2021

Neuroblastoma Recurrent Trial in Regensburg (Dasatinib, Rapamycin, Irinotecan)

Completed
  • Neuroblastoma Recurrent
  • Regensburg, Germany
    University Hospital Regensburg, Department of Pediatric Hematolo
Oct 2, 2020

Neuroblastoma Recurrent Trial in Singapore (Anti-GD2 in combination with NK cells)

Unknown status
  • Neuroblastoma Recurrent
  • Anti-GD2 in combination with NK cells
  • Singapore, Singapore
    National University Hospital
Mar 28, 2018

Neuroblastoma Recurrent Trial in Austria, Germany (ch14.18/CHO)

Unknown status
  • Neuroblastoma Recurrent
  • Graz, Austria
  • +3 more
Oct 2, 2014